Trial Profile
A clinical study to evaluate efficacy of eplerenone, a new drug for the treatment of acute heart failure while protecting myocardium (a randomized, double-blind, placebo-controlled study)
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Acute heart failure
- Focus Therapeutic Use
- Acronyms EARLIER001
- 13 Nov 2023 Results of Sub-Analysis assessing effect of Eplerenone on Cardiac Reverse Remodeling in Patients With Acute Heart Failure, presented at the American Heart Association Scientific Sessions 2023
- 19 Sep 2019 Status changed from active, no longer recruiting to completed.
- 17 Apr 2018 Planned End Date changed from 30 Jun 2018 to 6 Apr 2018.